HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 85.4%

Neg 85.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis downgrades Neuphoria Therapeutics (NASDAQ:NEUP) from Buy to Neutral.

Comments

No comments yet. Be the first!

HC Wainwright &amp; Co. Downgrades Neuphoria Therapeutics to Neutral